ANIK
Anika Therapeutics Inc
Anika Therapeutics Inc historical holders
total: 1
Engaged Capital Anika Therapeutics Inc transactions over time
- Total transactions:
- 4
- New positions:
- 1
- Sold out:
- 1
- Added:
- 1
- Reduced:
- 1
- Held since:
- 2018 Q2
- Held for:
- 3 quarters
- Latest activity:
- 2019 Q1
Glenn W. Welling has been an institutional investor in Anika Therapeutics Inc (ANIK) since 2018 Q2. According to 2026 Q1 report, Glenn W. Welling doesn't hold any shares. The fund/company first acquired ANIK in 2018 Q2, initially purchasing 262,547 shares. Since the initial investment, Engaged Capital has made 3 more transactions in this position.
When did Glenn W. Welling exit their ANIK position?
Glenn W. Welling no longer holds Anika Therapeutics Inc (ANIK). They sold off their entire position in 2019 Q1, closing out an investment that began in 2018 Q2.
When did Glenn W. Welling first invest in ANIK?
Glenn W. Welling first invested in Anika Therapeutics Inc (ANIK) in 2018 Q2 at the reported quarter-end price of $32.00 per share, acquiring 262,547 shares in their initial purchase.
What is Glenn W. Welling's average cost basis for ANIK?
Based on historical transaction data, Glenn W. Welling's estimated cost basis for Anika Therapeutics Inc (ANIK) is approximately $35.27 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $35.27
- Weighted AVG sell price:
- $33.61
ANIK transactions history by Engaged Capital
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2019 Q1
|
0.00%
|
$33.61
|
-100% (-374,926)
|
|||
|
2018 Q4
|
2.34%
|
$33.61
|
-3.10% (-12,000)
|
|||
|
2018 Q3
|
2.29%
|
$42.18
|
+47.37% (+124,379)
|
|||
|
2018 Q2
|
1.06%
|
$32.00
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.